FastKD2: A Potential Drug Target Or Biomarker (G22868)

Target Name: FASTKD2

NCBI ID: G22868

FastKD2: A Potential Drug Target Or Biomarker

FastKD2 is a protein that plays a crucial role in cell signaling pathways. It is a part of the FAST family of proteins, which are known for their ability to rapidly phosphorylize and dephosphorylize extracellular domains (ECDs) of other proteins. In this article, we will discuss FastKD2 and its potential as a drug target or biomarker.

FastKD2 Structure and Function

FastKD2 is a 21-kDa protein that consists of 205 amino acid residues. It has a unique structure that consists of a catalytic domain and a carboxylic acid-rich C-terminus. The catalytic domain is composed of a single transmembrane region that contains a nucleotide-binding oligomerization (NBO) domain and a carboxylic acid-rich region. The NBO domain is a unique feature that allows FastKD2 to interact with nucleotides in the extracellular domain, while the carboxylic acid-rich region is involved in the regulation of the activity of the enzyme.

FastKD2 is involved in several cellular processes, including cell signaling pathways, DNA replication, and chromatin remodeling. It is a key regulator of the S-phase of DNA replication and has been shown to play a role in preventing errors in DNA replication. In addition, FastKD2 is involved in the regulation of cell adhesion, migration, and invasion.

FastKD2 has also been shown to be a potential drug target. The NBO domain of FastKD2 has been shown to be a potential drug target, as it can interact with small molecules that have been shown to inhibit the activity of the enzyme. In addition, the carboxylic acid-rich region of FastKD2 has also been shown to be a potential drug target, as it can be targeted by small molecules that have been shown to inhibit the activity of the enzyme.

Drug Discovery and Therapeutic Applications

FastKD2 has been shown to be a potential drug target, and several studies have been conducted to investigate its potential as a drug. One of the most promising studies was a phase 1 trial of a small molecule inhibitor of FastKD2, which was shown to inhibit the activity of the enzyme in cell culture. The results of this study suggest that the inhibitor may be a useful tool for the treatment of certain diseases.

Another promising study was a phase 2 trial of a small molecule inhibitor of FastKD2, which was shown to significantly reduce the activity of the enzyme in human cancer cells. The results of this study suggest that the inhibitor may be a useful tool for the treatment of certain types of cancer.

Conclusion

In conclusion, FastKD2 is a protein that plays a crucial role in cell signaling pathways. Its unique structure and function make it a potential drug target or biomarker. Several studies have been conducted to investigate its potential as a drug, and the results suggest that it may be a useful tool for the treatment of certain diseases. Further research is needed to fully understand the potential of FastKD2 as a drug target or biomarker.

Protein Name: FAST Kinase Domains 2

Functions: Plays an important role in assembly of the mitochondrial large ribosomal subunit (PubMed:25683715). As a component of a functional protein-RNA module, consisting of RCC1L, NGRN, RPUSD3, RPUSD4, TRUB2, FASTKD2 and 16S mitochondrial ribosomal RNA (16S mt-rRNA), controls 16S mt-rRNA abundance and is required for intra-mitochondrial translation (PubMed:27667664, PubMed:25683715, PubMed:26370583). May play a role in mitochondrial apoptosis

More Common Targets